Hospital
UPMC Lititz
UPMC Lititz was paid $2.49M by Medicaid between Oct 2019 and Dec 2024, across 115 billing codes. Its largest line is 99284, emergency room visit (serious) — 35% of everything it billed.
33Billing provider infoUPMC LITITZ
LITITZ, PA 17543
LITITZ, PA 17543
33aNPI1285167916assigned 04/10/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.49M
24GClaims100,371
24DCodes billed115
24AFirst – last monthOct 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#85 of 154
Median peer was paid$2.82M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 94 | $2K | |
| 2020 | 7,253 | $151K | |
| 2021 | 37,099 | $878K | |
| 2022 | 19,392 | $496K | |
| 2023 | 19,741 | $470K | |
| 2024incomplete | 16,792 | $496K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 9,898 | 9,511 | $868K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 5,985 | 5,829 | $393K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.9% | 4,607 | 4,383 | $123K |
| 80050 | General health panel | 4.4% | 2,425 | 2,381 | $109K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 892 | 845 | $100K |
| 80053 | Comprehensive metabolic panel | 4.0% | 9,548 | 9,057 | $100K |
| 80061 | Lipid panel | 2.6% | 4,679 | 4,600 | $66K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 347 | 344 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 11,406 | 10,783 | $59K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 637 | 579 | $57K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.0% | 1,360 | 1,327 | $50K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 1,084 | 1,066 | $39K |
103 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.4% | 1,100 | $36K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 368 | $32K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 1,670 | $30K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 2,617 | $26K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,503 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,325 | $22K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 312 | $19K |
| 82607 | <1% | 1,702 | $18K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 193 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 678 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,005 | $16K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 262 | $16K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 202 | $11K |
| 81001 | <1% | 4,036 | $10K | |
| 84702 | <1% | 600 | $10K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,021 | $10K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 331 | $10K |
| 82728 | <1% | 745 | $9K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 367 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 288 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 34 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 570 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 273 | $7K |
| 84484 | <1% | 698 | $6K | |
| 84439 | <1% | 714 | $6K | |
| 83540 | <1% | 649 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 651 | $5K |
| 86803 | <1% | 256 | $5K | |
| 85027 | <1% | 698 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 190 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 75 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 175 | $4K |
| 83690 | <1% | 799 | $4K | |
| 76642 | <1% | 83 | $4K | |
| 83735 | <1% | 539 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,596 | $3K |
| 83550 | <1% | 611 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 353 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 46 | $3K |
| 82570 | <1% | 315 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 325 | $2K |
| 84703 | <1% | 202 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 211 | $2K |
| 81025 | <1% | 563 | $2K | |
| 82043 | <1% | 216 | $2K | |
| 93971 | <1% | 31 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 26 | $2K |
| 94726 | <1% | 54 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $1K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 31 | $1K |
| 94729 | <1% | 40 | $1K | |
| 97597 | <1% | 58 | $1K | |
| 80081 | <1% | 14 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 52 | $997.82 |
| 87340 | <1% | 64 | $910.37 | |
| 82746 | <1% | 109 | $901.88 | |
| 76857 | <1% | 43 | $854.90 | |
| 85652 | <1% | 262 | $828.16 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 16 | $819.26 |
| 73630 | <1% | 84 | $806.21 | |
| 85610 | <1% | 240 | $793.41 | |
| 86850 | <1% | 106 | $735.14 | |
| 86140 | <1% | 214 | $678.24 | |
| 86901 | <1% | 161 | $617.80 | |
| 86900 | <1% | 162 | $610.30 | |
| 87150 | <1% | 13 | $573.10 | |
| 86592 | <1% | 132 | $561.97 | |
| 87186 | <1% | 75 | $552.59 | |
| 87077 | <1% | 77 | $537.98 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,813 | $536.40 |
| 85379 | <1% | 43 | $455.98 | |
| J3490 | Unclassified drugs | <1% | 518 | $436.69 |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $404.45 |
| 94060 | <1% | 40 | $352.26 | |
| 83605 | <1% | 52 | $346.52 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $309.00 |
| J2704 | Injection, propofol, 10 mg | <1% | 510 | $300.50 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 27 | $296.80 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 261 | $273.02 |
| 85730 | <1% | 30 | $189.01 | |
| 87081 | <1% | 30 | $183.09 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,384 | $182.62 |
| 74018 | <1% | 12 | $151.15 | |
| 81003 | <1% | 46 | $140.07 | |
| 80076 | <1% | 13 | $136.02 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 528 | $115.45 |
| 84156 | <1% | 35 | $114.40 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 321 | $97.14 |
| 99000 | <1% | 16 | $96.00 | |
| 82565 | <1% | 12 | $90.13 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 789 | $79.35 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 419 | $77.32 |
| 84520 | <1% | 12 | $76.50 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 17 | $75.45 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 38 | $17.82 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 296 | $10.15 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 693 | $4.80 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 13 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 39 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 82 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 94 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 34 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMITSTIFER, GREGORY (CFO)
| Provider | Location | Paid |
|---|---|---|
| UPMC Pinnacle Hospitals | Harrisburg, PA | $26.92M |
| UPMC Memorial | York, PA | $6.74M |
| UPMC Carlisle | Carlisle, PA | $3.56M |
| UPMC Hanover | Hanover, PA | $2.92M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.